Skip to main content
Fig. 7 | Breast Cancer Research

Fig. 7

From: Mcl-1 confers protection of Her2-positive breast cancer cells to hypoxia: therapeutic implications

Fig. 7

Genetically and pharmacologically targeting Mcl-1 induces cell death in brain-primed Her2 inhibitor-resistant Her2-positive BC cells. a, b Genetic depletion of Mcl-1 induces apoptosis in both maternal Her2 inhibitor-resistant Her2-positive JIMT-1 cells as well as in brain-primed JIMT-1 BR3 cells. a BC cells were transfected with siMCL1 for 2 days and exposed to hypoxia for 6 hours. Whole-cell extracts were analyzed by immunoblotting with indicated antibodies. Immunoblotting for Erk2 confirmed equal protein loading. b BC cells were transfected with siMCL1 for 30 hours and then exposed to hypoxia for 2 days. Cell survival was determined by AlamarBlue® assay. Data represent mean ± SD for triplicate samples. Results shown are representative of three independent experiments. c EU-5346 overcomes Her2 inhibitor resistance in brain-primed Her2-positive BC cells. BC cells were treated with indicated drugs for 3 days and then exposed to hypoxia during the last 6 hours. Whole-cell extracts were analyzed by immunoblotting with indicated antibodies. Immunoblotting for Erk2 confirmed equal protein loading. d EU-5346 inhibits proliferation of brain-primed Her2-positive BC cells in a dose-dependent manner. BC cells were treated with EU-5346 for 3 days under hypoxic conditions. [3H]-thymidine was added during the last 8 hours. Data represent mean ± SD for triplicate samples. Results shown are representative of three independent experiments. C control (dimethyl sulfoxide), E EU-5346, Erk2 extracellular signal-regulated kinase 2, Her2 human epidermal growth factor receptor 2, Hif hypoxia-inducible factor, kD kilodalton, L lapatinib, Mcl-1 myeloid cell leukemia-1, T trastuzumab

Back to article page